The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study of olinvacimab (O) with pembrolizumab (P) in patients with recurrent glioblastoma (rGBM).
 
Anna K. Nowak
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Douglas Pharmaceuticals; Douglas Pharmaceuticals; Epizyme; Merck Sharp & Dohme; Roche; Sellas Life Sciences; Trizell
Research Funding - AstraZeneca (Inst); Douglas Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; Boehringer Ingelheim
 
Lawrence Cher
Honoraria - PharmAbcine
Consulting or Advisory Role - PharmAbcine
Research Funding - PharmAbcine (Inst)
 
Samantha Bowyer
No Relationships to Disclose
 
Hui Kong Gan
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Eisai; Merck Serono; Merck Serono
Research Funding - AbbVie
 
Anne Poh Long
No Relationships to Disclose
 
Adithya Balasubramanian
No Relationships to Disclose
 
Seon Young Lee
Employment - PharmAbcine
Leadership - PharmAbcine
Stock and Other Ownership Interests - PharmAbcine
Honoraria - PharmAbcine
 
Weon Sup Lee
Employment - PharmAbcine
Leadership - PharmAbcine
Stock and Other Ownership Interests - PharmAbcine
 
Jin-San Yoo
Employment - PharmAbcine
Leadership - PharmAbcine
Stock and Other Ownership Interests - PharmAbcine
Honoraria - PharmAbcine
Patents, Royalties, Other Intellectual Property - PharmAbcine